APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects; it suppresses prostaglandin production by acetylating the active site (serine 516) of COX-2, which is overexpressed in colorectal cancer (CRC) and exhibits pleiotropic pro-tumorigenic activities; additionally, APHS inhibits the WNT pathway, providing an anti-tumor mechanism independent of COX-2 inhibition.